Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Denver-based biopharmaceutical firm GlobeImmune has initiated an early phase study of one of its tarmogens, GI-5005, for the treatment of chronic hepatitis C infection.
Subscribe to our email newsletter
The phase Ib study is a dose-escalation, multi-center trial evaluating the safety, immunogenicity, and efficacy of GI-5005.
GI-5005 is designed to express antigens that fight hepatitis C infection in a way that is similar to the response occurring in the minority of individuals whose immune systems successfully deal with hepatitis C infection. As such the company believes that the GI-5005 tarmogen may represent a successful approach to treating this difficult disease.
“Hepatitis C is an area of major unmet medical need,” said Dr Timothy Rodell, CEO of GlobeImmune. “We are hopeful that GI-5005 will ultimately be able to treat the significant proportion of patients for whom there is currently no effective therapy.”
Chronic hepatitis C infection, a viral liver disease, is a global health epidemic. Currently, there are approximately 170 million people worldwide who are infected with the hepatitis C virus. Approximately 20-30% of all hepatitis C patients will face life threatening complications as a result of their disease.